{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:19:55Z","timestamp":1785529195494,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.06.008","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T21:29:20Z","timestamp":1689456560000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-7621","authenticated-orcid":false,"given":"Francis J.","family":"Gilchrist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-2518","authenticated-orcid":false,"given":"Stephanie","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-728X","authenticated-orcid":false,"given":"Susanna A.","family":"McColley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Tiddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-789X","authenticated-orcid":false,"given":"Gary","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Stehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhsen","family":"Alani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Gurtovaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1787-9010","authenticated-orcid":false,"given":"Mark","family":"Bresnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biliana","family":"Frankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.06.008_bib0001","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.06.008_bib0002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.008_bib0003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ppul.1950190103","article-title":"Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis","volume":"19","author":"Pamukcu","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.06.008_bib0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jcf.2023.06.008_bib0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jcf.2019.10.014","article-title":"Risk factors for progression of structural lung disease in school-age children with cystic fibrosis","volume":"19","author":"Svedberg","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.008_bib0006","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1183\/09031936.00043108","article-title":"Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis","volume":"33","author":"Douglas","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.06.008_bib0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcf.2020.10.008","article-title":"Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"20","author":"Jackson","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.008_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2012.07.008","article-title":"Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa","volume":"12","author":"Schelstraete","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.008_bib0009","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"4","author":"Langton Hewer","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2023.06.008_bib0010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Hewer","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.06.008_bib0011","unstructured":"EMA. Cayston (aztreonam). Summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cayston-epar-product-information_en.pdf; 2021 (accessed: 6 December 2022)."},{"key":"10.1016\/j.jcf.2023.06.008_bib0012","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jcf.2023.06.008_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2014.06.003","article-title":"Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study","volume":"14","author":"Tiddens","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.008_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10880-014-9396-1","article-title":"Parent routines for managing cystic fibrosis in children","volume":"21","author":"Grossoehme","year":"2014","journal-title":"J Clin Psychol Med Settings"},{"key":"10.1016\/j.jcf.2023.06.008_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/PPA.S53653","article-title":"Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes","volume":"10","author":"Bodn\u00e1r","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jcf.2023.06.008_bib0016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17476348.2017.1280399","article-title":"Adherence to therapies in cystic fibrosis: a targeted literature review","volume":"11","author":"Narayanan","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2023.06.008_bib0017","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1378\/chest.13-1926","article-title":"Pulmonary medication adherence and health-care use in cystic fibrosis","volume":"146","author":"Quittner","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2023.06.008_bib0018","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report","volume":"153","author":"Farrell","year":"2008","journal-title":"J Pediatr"},{"issue":"s","key":"10.1016\/j.jcf.2023.06.008_bib0019","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2023.06.008_bib0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.06.008_bib0021","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.06.008_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.008_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcf.2008.08.002","article-title":"Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods","volume":"8","author":"Pressler","year":"2009","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323008214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323008214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:11:44Z","timestamp":1767240704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323008214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323008214"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.06.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}